Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Product Highlight-Skycellflu

27 Sep 2018
SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics

The World’s First Cell Culture-Derived Inactivated Influenza Vaccine1


• Optimized immunogenicity with >95% seroprotection rates against all strains in adults and >90% in children ≥3 years2-3
• Tolerable safety profiles in adults and children ≥3 years2-3
• Contains no eggs, no preservatives and no antibiotics1

References:
1. Korea Ministry of Food and Drug Safety. [http://www.mfds.go.kr/eng/brd/m_30/view.do?seq=70648]. Accessed July 24, 2018.
2. Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Hum Vaccin Immunother 2017; 13(7): 1653-1660.
3. Kim YK, Eun BW, Lee TJ, et al. Immunogenicity and Safety of a Cell Culture-Derived Inactivated Quadrivalent Influenza Vaccine (NBP607-QIV) in South Korean Children and Adolescents: A Randomized, Double-Blind, Multi-Center, Phase 3 Clinical Trial. Open Forum Infect Dis 2016; Vol 3(Suppl 1): 763.

Further information is available in section 12b, New In This Issue and mims.com
Full prescribing information is available upon request.                                                                                                                                                                                                                                                                                                MY-SCF-000001-08/18

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).